HAND2 and endometrial cancer: Interestingly, the effect of HAND2 methylation on endometrial cancer risk is mediated by methylation and silencing of HAND2 in endometrial stromal non-immune cells, increasing paracrine signaling through release of fibroblast growth factors thus sensitizing the endoemtrial epithelial cells to oncogenic estrogen [29].